Upadacitinib for stubborn eyelid dermatitis
Treatments studied
Part of Skin clinical trials.
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have had eyelid dermatitis (a red, itchy rash on the eyelids) for at least 2 months.
- You have tried at least one prescription cream (such as a steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib) that did not clear the rash.
- You are willing to stop using any other topical medication on your eyelids for one week before starting the study drug.
- You do not have a history of allergic reaction to upadacitinib, heart disease, stroke, or active infections like tuberculosis, hepatitis B, or hepatitis C.
- If you are a woman who could become pregnant, you agree to use effective birth control during treatment and for 4 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This trial tests a drug called upadacitinib for people who have both a liver condition (primary biliary cholangitis or primary sclerosing cholangitis) and atopic dermatitis (eczema) with moderate to severe itching. The goal is to see if the drug can help control both the liver and skin problems.
This trial tests a daily pill (upadacitinib) to see if it can improve vitiligo after an initial treatment (NECS). It is for people whose vitiligo is stable and covers a limited area.
This study tests whether a medication called upadacitinib can help people with eosinophilic esophagitis (a condition where too many white blood cells called eosinophils build up in the food tube) who are not getting better with their current steroid treatment. The medication works by reducing inflammation in the esophagus.
This trial tests a pill called upadacitinib (a JAK inhibitor) for people with erosive lichen planus affecting the mouth or scalp. It aims to see if the drug can reduce inflammation and improve symptoms when topical steroids aren't enough.
This trial tests whether upadacitinib, an oral medication, is safe and effective for people with relapsing polychondritis that hasn't improved enough with standard treatments. It aims to reduce inflammation and control symptoms.
Hear when a new Eyelid Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.